CHEMED CORP (CHE)

Insider Trading Filed: 2026-05-08

Director Patrick P. Grace sold 60 shares of CHE at $425.78 per share on 05/08/2026, generating approximately $25,547 in proceeds, indicating a modest insider sale rather than a significant position reduction.
Grace's remaining beneficial ownership of 3,337 shares suggests he maintains a meaningful stake in the company despite the sale, with no apparent loss of confidence in Chemed's prospects.
The sale appears to be a routine transaction for a director-level executive, with no indication of distress selling or large-scale insider liquidation that would raise red flags for investors.

Insider Trading Filed: 2026-05-04

CEO Kevin McNamara sold 2,000 shares of CHE on May 1, 2026 at a weighted average price of $421.13, with prices ranging from $418.99 to $424.95, reducing his direct beneficial ownership to 90,219 shares.
This represents a relatively modest insider sale of approximately 2.2% of the reported beneficial ownership, suggesting measured portfolio rebalancing rather than a significant loss of confidence in the company.
The sale occurred at a time when the stock was trading near $421, indicating the executive executed the transaction at market prices without any apparent urgency or distressed selling patterns.

Quarterly Report Filed: 2026-04-28

The filing shows CHEMED operating two distinct business segments (VITAS and Roto-Rooter) with detailed revenue breakdowns by service type and payer mix (Medicare, Medicaid, Commercial), indicating strong operational transparency and diversified revenue streams across healthcare and home services.
The company maintains multiple financing arrangements including a revolving credit facility with an expansion feature and letter of credit provisions as of March 31, 2026, suggesting active capital management and liquidity access for growth initiatives.
Detailed performance metrics are tracked for executive compensation tied to both earnings per share targets and total shareholder return targets (as of February 13, 2026), indicating management incentives are aligned with shareholder value creation and financial performance.

Current Report Filed: 2026-04-23

Chemed Corporation filed an 8-K to announce Q1 2026 financial results for the quarter ended March 31, 2026, indicating the company is maintaining regular reporting cadence and transparency with investors.
The filing is a straightforward earnings announcement with no indication of material events, executive changes, significant agreements, or operational disruptions, suggesting stable business operations during the quarter.
The document was signed by Michael D. Witzeman as Executive Vice President and Chief Financial Officer, confirming continuity in the company's financial leadership and decision-making authority.

Current Report Filed: 2026-04-13

Chemed Corporation has renewed its $450 million senior secured credit facilities, providing the company with continued access to flexible financing options.
The credit facilities include a five-year $450 million revolving credit facility, with the interest rate based on the secured overnight financing rate (SOFR) plus an additional tiered rate.
The agreement also includes an expansion feature that allows Chemed to increase its revolving credit by an additional $250 million, potentially providing more funding capacity for future growth or strategic initiatives.

Insider Trading Filed: 2026-03-30

Kevin J. McNamara, the President and CEO of Chemed Corp, has sold 1,500 shares of the company's capital stock at an average price of $369.37.
Following this transaction, McNamara still holds a direct ownership of 92,219 shares in the company.
The filing indicates that the sale was conducted pursuant to a Rule 10b5-1 trading plan, which suggests a pre-planned transaction.

Annual Report Filed: 2026-02-27

Chemed Corporation's 10-K filing for fiscal year 2025 indicates continued revenue growth and profitability in its Vitas healthcare segment, driven by strong performance in routine home care, inpatient care, and care services across Medicare, Medicaid, and commercial insurance payers.
The company's Roto-Rooter segment also shows positive trends, with increases in revenue from water restoration, short-term core service jobs, and plumbing services.
Chemed has maintained a consistent capital allocation strategy, including the use of treasury stock and share-based compensation programs to incentivize and retain key employees.

Current Report Filed: 2026-02-25